Qualitek Labs Limited Investors Presentation for Half and Financial Year ended 31st March 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Qualitek Labs reported strong FY25 results with standalone revenue up 57% YoY at ₹45.8 Cr, EBITDA at ₹11.8 Cr (+46% YoY), and PAT at ₹5.3 Cr (+23% YoY). Consolidated FY25 revenue stood at ₹70.2 Cr (including ITC Labs and Quality and Testing Infosolution acquisitions completed in September 2024) with EBITDA of ₹16.8 Cr and PAT of ₹7.7 Cr. The company recently listed on BSE in 2025 and promoters hold 54% stake. Key milestones include completion of pan-India drinking water testing for Ministry of Jal Shakti (1.47 lakh samples), AMRUT Yojna project, and new lab setups in Noida, Bhubaneswar, and Baddi. The company guided for 2X revenue growth every 2 years and improving EBITDA margin to 30%, with plans for inorganic expansion including acquisitions in South and West India.
Strong topline growth driven by acquisitions and expansion into new segments (EV battery testing, minerals, defence) signals robust business momentum. Margin guidance to 30% EBITDA and revenue doubling every 2 years indicates management confidence, though FY25 standalone PAT margin dipped to 11% from 15% due to initial setup costs for mineral business and Noida lab.